February 1, 2016: Here are four stocks trading with heavy volume among 96 equities making new 52-week lows today. Gilead Sciences Inc. (NASDAQ: GILD) dropped about 0.9% on Monday to post a…
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher…
January 29, 2016: Here are four stocks trading with heavy volume among 119 equities making new 52-week lows today. Gilead Sciences Inc. (NASDAQ: GILD) dropped about 5.8% on Friday to post a…
Short interest increased in most of these selected biotech stocks for the most recent settlement date.
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
Merrill Lynch sees some stabilization in the hepatitis C market in 2016 that might allow Gilead Sciences to stay above water this year.
Friday's top analyst calls include Best Buy, 3D Systems, Electronic Arts, Gilead Sciences, Nokia, Shire and United Rentals.
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny. These four companies with promising candidates all have dates with the agency…
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
24/7 Wall St. is taking a look at the bottom line for companies in the S&P 500 going into 2016, and we have chosen some of the least expensive stocks for the…
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
New data suggests that the stock market's performance in 2015 was bolstered or supported by the largest S&P 500 companies buying back their own stock.
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
